India Health Fund (IHF), a Tata Trusts initiative, is poised to transform tuberculosis (TB) screening at scale by enabling the development of the world’s most affordable molecular screening tool for TB.
Supporting D-Nome, a deep-tech startup based out of Hyderabad, IHF will enable development and validation of indigenously developed D-Nome’s D-ISO NAAT molecular screening platform for TB, expanding equitable access to molecular TB screening at primary health centres (PHCs) and strengthening health systems. D-Nome’s D-ISO NAAT platform offers an end-to-end PHC-compatible molecular platform.
India continues to bear the highest global burden of tuberculosis, accounting for nearly 25–27% of all cases worldwide, with an estimated ~2.7 million cases in 2024. While molecular diagnostics have improved accuracy, their accessibility at the last mile is limited by cost, infrastructure, and operational complexity.
There is a critical need for solutions that combine molecular- grade performance with affordability and decentralised deployment at PHCs. D-Nome’s D-ISO NAAT platform addresses these challenges by offering a cost-effective solution with operational simplicity and minimal infrastructure requirements.
This collaboration aims to:
